Hauser SL, Cross AH, Winthrop K, Wiendl H, et al. Safety experience with continued exposure to ofatumumab in patients with relapsing forms of multiple sclerosis for up to 3.5 years. Mult Scler 2022 Mar 1:13524585221079731. doi: 10.1177/13524585221079731.
PMID: 35229668